Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Opexa Therapeutics has reported that the independent data safety monitoring board of its ongoing 150-patient Phase IIb safety and efficacy study of Tovaxin in multiple sclerosis recommended that the trial be continued as scheduled.
Subscribe to our email newsletter
The data safety monitoring board (DSMB) meeting reviewed 28-week data for approximately 50% of the patients in the study. The DSMB noted in their report very few dropouts and that the study appears to be proceeding well. In addition, the report indicated that baseline MRI data is consistent with the assumptions used in the design of the study.
David McWilliams, president and CEO of Opexa said: ” We have delivered all Tovaxin doses to patients in the study and now look forward to presenting 52-week topline results of the TERMS Phase IIb study in September.”